RayzeBio upsizes its offering, Neumora sticks to original plan in Friday IPO doubleheader

Two Phase III biotechs will join the Nasdaq Friday morning, with radiopharma startup RayzeBio and brain disease drug developer Neumora raising $311 million and $250 million, respectively.

RayzeBio and Neumora wooed investors during a relatively icy IPO market, which is beginning…
Click here to view original post